1,294
Views
3
CrossRef citations to date
0
Altmetric
Brief Report

Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors

, , , , &
Pages 1822-1833 | Received 05 Nov 2019, Accepted 14 Sep 2020, Published online: 24 Sep 2020

References

  • Graham DK, DeRyckere D, Davies KD, Earp HS. The tam family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014;14:769–85.
  • Akalu YT, Rothlin CV, Ghosh S. Tam receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev 2017;276:165–77.
  • Myers KV, Amend SR, Pienta KJ. Targeting tyro3, axl and mertk (tam receptors): implications for macrophages in the tumor microenvironment. Mol Cancer 2019;18:94.
  • Vouri M, Hafizi S. Tam receptor tyrosine kinases in cancer drug resistance. Cancer Res 2017;77:2775–8.
  • Wong KM, Horton KJ, Coveler AL, et al. Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (pegph20). Curr Oncol Rep 2017;19:47.
  • Crittenden MR, Baird J, Friedman D, et al. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget 2016;7:78653–66.
  • Yan S, Vandewalle N, De Beule N, et al. Axl receptor tyrosine kinase as a therapeutic target in hematological malignancies: focus on multiple myeloma. Cancers (Basel) 2019;11:1727.
  • Holland SJ, Pan A, Franci C, et al. R428, a selective small molecule inhibitor of axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010;70:1544–54.
  • Kasikara C, Davra V, Calianese D, et al. Pan-tam tyrosine kinase inhibitor bms-777607 enhances anti-pd-1 mab efficacy in a murine model of triple-negative breast cancer. Cancer Res 2019;79:2669–83.
  • Agha A, Tarhini AA. Adjuvant therapy for melanoma. Curr Oncol Rep 2017;19:36.
  • Liu J, Yang C, Simpson C, et al. Discovery of novel small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med Chem Lett 2012;3:129–34.
  • Tondo G, Perani D, Comi C. Tam receptor pathways at the crossroads of neuroinflammation and neurodegeneration. Dis Markers 2019;2019:2387614.
  • Vollrath D, Yasumura D, Benchorin G, et al. Tyro3 modulates mertk-associated retinal degeneration. PLoS Genet 2015;11:e1005723.
  • Lam SC, Saubern G, Adams S, et al. A. New aryl/heteroaryl c-n bond cross-coupling reactions via arylboronic acid/cupric acetate arylation. Tetrahedron Lett 1998;39:2941–4.
  • Monnier F, Taillefer M. Catalytic C-C, C-N, and C-O ullmann-type coupling reactions. Angew Chem Int Ed Engl 2009;48:6954–71.